Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Coadministered with a Quadrivalent Influenza Vaccine in Adults 50 Years and Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
نویسندگان
چکیده
LB-7. Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Coadministered with a Quadrivalent Influenza Vaccine in Adults 50 Years and Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine Roger Baxter, MD, FIDSA; H. Jackson Downey, MD; Scott D. Patterson, PhD; Vani Sundaraiyer, PhD; Wendy Watson, MD; Keri Clarke, MD; William C. Gruber, MD, FIDSA; Daniel A. Scott, MD; Allison Thompson, MD, FAAP; Beate SchmoeleThoma MD; Kaiser Permanente Vaccine Study Center, Oakland, California; Jacksonville Center for Clinical Research, Jacksonville, Florida; Pfizer Vaccine Research, Collegeville, Pennsylvania; inVentiv Health Clinical, LLC, Princeton, New Jersey; Pfizer Inc, Walton Oaks, United Kingdom; Pfizer Vaccine Research, Pearl River, New York; Pfizer Pharma GmbH, Berlin, Germany
منابع مشابه
Conjugate and 23-valent pneumococcal polysaccharide booster vaccination in asplenic patients with thalassemia major: A randomized clinical trial study
Background: Pneumococcal vaccine provides protection against invasive pneumococcal disease in population at risk. This study was conducted to compare the antibody response to 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in patients with thalassemia major. Methods: A randomized cross-over clinical trial was performed on 50 asplenic patients with t...
متن کاملImmunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
BACKGROUND The currently recommended single dose of the 23-valent pneumococcal free polysaccharide vaccine (PPSV23) for adults 65 years of age and older does not provide extended protection into older age. This reflects a significant unmet medical need for alternative strategies to protect older adults against pneumococcal infection, which may be met by the 13-valent polysaccharide conjugate va...
متن کاملImmunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years. An open-label trial.
This open-label study was designed to assess immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) when administered to Japanese adults aged ≥50 years not previously vaccinated with 23-valent pneumococcal polysaccharide vaccine and to compare this Japanese study population with similar study populations in the United States (US; 50-64 years age group) and European Union ...
متن کاملImmunogenicity of 23-Valent Pneumococcal Vaccine in Children with Systemic Lupus Erythematosus
Background: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease which is characterized by B-cell abnormality and auto-antibody generation. Since bacterial infections are the most important causes of mortality in these patients, pneumococcal vaccination is recommended for children with SLE. Objective: To investigate humoral immunity and specific-antibody formation in response to a...
متن کاملPneumococcal Conjugate Vaccine for Adults: A New Paradigm
A 13-valent pneumococcal conjugate vaccine has been studied in adults aged ≥ 50 years to compare the immune response to that induced by the 23-valent pneumococcal polysaccharide vaccine, which has been the standard of care over the past 30 years. The results demonstrate that adults, regardless of whether they are naive or previously vaccinated with the polysaccharide vaccine, have an overall su...
متن کامل